Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
- MACD is crossing MACD signal line at 0.3. MACD crossing signal line is bullish signal.
|Earning Growth (QoQ)||224%|
|Revenue Growth (QoQ)|
|Held by Institutions %||73%|
|1 Day Vol Adjusted Return||0.7|
|1 Month Vol Adjusted Return||-2.1|
|3 Month Vol Adjusted Return||3.0|
|6 Month Vol Adjusted Return||4.2|
|20 Days SMA Price ZScore||1.9|
|50 Days SMA Price ZScore||0.1|
|12 -26 Days PPO||-0.3|
|1 Month Average Short Volume Ratio||32.4|
|1 Day Volume Change ZScore||-0.9|
|1 Month Daily Vol||1.0|
QIAGEN's (QGEN) QIAreach QuantiFERON-TB test is now accessible in high burden, low-resource regions.
VENLO, the Netherlands, October 20, 2021--QIAGEN N.V. to release results for Q3 2021 and first nine months of 2021
HILDEN, Germany & GERMANTOWN, Md., October 19, 2021--QIAGEN launches novel QIAreach QuantiFERON-TB tuberculosis test for high-burden regions
Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Qiagen (QGEN) could produce exceptional returns because of its solid growth attributes.
New product approvals, partnerships in the diagnostic solutions category and sustained success in other product areas are likely to have contributed to QIAGEN's (QGEN) growth.
PerkinElmer's (PKI) unit receives FDA's EUA nod for its Anti-SARS-CoV-2 S1 Curve ELISA (IgG) that could aid in future understanding and provide insights on immune responses to SARS-CoV-2.
Thermo Fisher's (TMO) wastewater surveillance method is set to identify asymptomatic carriers on college campuses to monitor regional spread among communities.
QIAGEN's (QGEN) NeuMoDx platforms offer a unique combination of speed, flexibility, throughput and ease of use for molecular diagnostics testing, including laboratory-developed tests.